Low-dose corticosteroids were employed as first-line treatment to manage CRS in patients with B-ALL undergoing CD19- or CD22-CAR-T cell therapy, encompassing both children and adults; however, a comparison of survival between the two groups was not conducted. Here, CD19 is linked to congenital rubella syndrome.